Michelle Dipp, MD PhD is a Co-Founder and Managing Partner of Biospring Partners. She has over a decade of private equity and venture capital expertise in life sciences. Her background in thought leadership and research have been cited over 1000 times on Google Scholar. She currently serves on the Board of Abzena.
Prior to co-founding this new business, Michelle was a Managing Director at General Atlantic, a global growth equity firm based in New York. While at General Atlantic Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.
A new $200 million fund from Accolade Partners will help invest in funds started by underrepresented groups including Biospring Partners. Learn why more capital is going to these funds that outperform the market.
Biospring Partners is pround to announce that they have appointed Drew Pearson as Head of Portfolio Management. The life science venture capital firm has added several industry leaders to its Advisory Board.
Welp Magazine gives their top 100 women-led investment firms to follow. In their November, 2020 review, they list Longwood Fund and co-founder Michelle Dipp in their diversity spotlight.
A conversation about Life Science investment trends with Michelle Dipp, MD PhD, Co-Founder and Managing Partner at Biospring Partners.